内容概要：在中国，开放吻合器行业市场规模呈现下降态势，2017-2019年中国开放吻合器市场规模持续上升，2020年受疫情影响下降至15.3亿元，2021年 虽然有所恢复，但2022-2024年中国开放吻合器行业市场规模逐年下降，2024行业市场规模达到14.1亿元，同比下降2.1%。中国开放吻合器市场规模下降， 其主要原因是随着外科医疗技术的迭代升级，微创理念已成为临床诊疗的主流趋势，而腔镜吻合器作为微创手术的核心器械，凭借创伤小、术后恢复快、吻 合精度高的优势，快速替代开放吻合器的传统应用场景。不过，开放吻合器在基层医疗、复杂开放手术、急诊等场景仍具备不可替代性，未来市场规模或趋 于稳定，但在整体吻合器市场中的占比预计将持续走低，行业竞争焦点将转向产品升级与成本控制。 相关上市企业：东星医疗（301290）、乐普医疗（300003）、戴维医疗（300314）、天臣医疗（688013）等。 相关企业：广州德脉医疗器械有限公司、广东实联医疗器械有限公司、常州洛克曼医疗器械有限公司、常州安康医疗器械有限公司、苏州凯尔得医疗器械有 限公司、常州瑞索斯医疗设备有限公司、苏州贝诺医疗器械有限公司、天津瑞奇外科器械股份 ...

"当竞争演变为维持高利润的'默契'，创新便失去了动力。"天臣医疗联合创始人陈望东认为，好的技术 需要具备普惠性，天臣医疗选择成为一名"革新者"，以持续创新打破长期固化的市场格局 成立于2003年的天臣国际医疗科技股份有限公司（简称"天臣医疗"），专注高端外科手术吻合器研发， 已形成覆盖心胸、胃肠、普外等多领域的五大类产品体系，成为国内高端吻合器出口的领先企业。今年 前三季度，公司实现营收2.44亿元、净利润7194.57万元，同比分别增长20.66%和68.29%。 ◎记者严曦梦 作为外科手术台上的常用器械，吻合器常被医生称作"订书机" ——轻轻一按，切割与缝合几乎同时完 成，缝合过程压缩到数秒之内。二十多年前，这一细分领域长期被国际巨头垄断。如今，一家中国企业 正凭借自主创新逐浪全球市场。 站在新的起点上，天臣医疗的目光已不再局限于单一器械。天臣医疗联合创始人陈望东近日在接受上海 证券报记者专访时表示，随着外科手术加速迈向微创化、智能化，手术机器人正成为下一轮产业竞争的 关键方向。天臣医疗将在这一全球竞逐的赛道中，聚焦开放式的智能手术平台，探索一条更具普惠性 的"中国方案"。 真创新打破"伪竞争" 走进天臣 ...

报告导读： 开放吻合器是吻合器的一种类型，主要用于传统的开放外科手术中，通过机械装置对组织进行切割和吻合，替代手工缝合。在中国，开放吻合器行业市场规 模呈现下降态势，2017-2019年中国开放吻合器市场规模持续上升，2020年受疫情影响下降至15.3亿元，2021年虽然有所恢复，但2022-2024年中国开放吻合 器行业市场规模逐年下降，2024行业市场规模达到14.1亿元，同比下降2.1%。中国开放吻合器市场规模下降，其主要原因是随着外科医疗技术的迭代升级， 微创理念已成为临床诊疗的主流趋势，而腔镜吻合器作为微创手术的核心器械，凭借创伤小、术后恢复快、吻合精度高的优势，快速替代开放吻合器的传统 应用场景。不过，开放吻合器在基层医疗、复杂开放手术、急诊等场景仍具备不可替代性，未来市场规模或趋于稳定，但在整体吻合器市场中的占比预计将 持续走低，行业竞争焦点将转向产品升级与成本控制。 基于此，依托智研咨询旗下开放吻合器行业研究团队深厚的市场洞察力，并结合多年调研数据与一线实战需求，智研咨询推出《2026-2032年中国开放吻合 器行业市场全景调研及发展趋向研判报告》。本报告立足开放吻合器新视角，聚焦行业核心议题 ...

关键词：开放吻合器行业产业链、开放吻合器行业市场规模、开放吻合器行业竞争格局、开放吻合器行 业发展趋势 一、开放吻合器行业相关概述 内容概要：在中国，开放吻合器行业市场规模呈现下降态势，2017-2019年中国开放吻合器市场规模持 续上升，2020年受疫情影响下降至15.3亿元，2021年虽然有所恢复，但2022-2024年中国开放吻合器行 业市场规模逐年下降，2024行业市场规模达到14.1亿元，同比下降2.1%。中国开放吻合器市场规模下 降，其主要原因是随着外科医疗技术的迭代升级，微创理念已成为临床诊疗的主流趋势，而腔镜吻合器 作为微创手术的核心器械，凭借创伤小、术后恢复快、吻合精度高的优势，快速替代开放吻合器的传统 应用场景。不过，开放吻合器在基层医疗、复杂开放手术、急诊等场景仍具备不可替代性，未来市场规 模或趋于稳定，但在整体吻合器市场中的占比预计将持续走低，行业竞争焦点将转向产品升级与成本控 制。 相关上市企业：东星医疗（301290）、乐普医疗（300003）、戴维医疗（300314）、天臣医疗 （688013）等。 相关企业：广州德脉医疗器械有限公司、广东实联医疗器械有限公司、常州洛克曼医疗器械 ...

迈瑞医疗认为，展望国内市场，短期的行业扰动无法避免，公司已经及时地调整了应对策略。首先，公 司认为国内业务最艰难的时刻已经过去；第二，当前的市场环境给了迈瑞加速国产扩容和加快行业集中 度提升这一历史性机遇，因此公司将国内业务考核的重心放在了市场份额上，尤其是重点考核IVD业务 大规模突破大样本量客户，国内各项业务的市占率均在稳步提升；第三，公司持续倾斜资源投入在流水 型业务和国际市场。微创外科中的高值耗材超声刀、腔镜吻合器有望从今年开始在国内放量，这部分业 务的市场容量远比传统生命信息与支持业务要大，同时未来的成长性也要比传统业务更强，并且得益于 海外高端客户的加速突破，国际业务后续的增长也将提速。 目前，迈瑞医疗正全力冲击全球医疗器械排名前20的目标。公司的监护仪、麻醉机、呼吸机、除颤仪、 血球、超声产品在全球的市场占有率维持前三的地位。随着"国际化""数智化""流水化"战略的发展，公 司有望向更高的市场地位发起冲击。 实际上，增持之初，李西廷就已公布了后续计划——未来6个月内，以自有资金继续在深交所以集中竞 价交易方式增持公司股份，拟增持计划总金额为2亿元，且增持不设价格区间，锁定期为增持计划实施 完成后 ...

公司核心创始人连续增持的背后，包含了对于迈瑞医疗未来发展的信心。从经营数据来看，尽管 2025年前三季度迈瑞医疗业绩因高基数等因素承压，但第三季度单季营收已实现同比增长1.53%，如期 迎来拐点。公司近期在互动易平台表示，预计明年国内业务有望恢复正增长，2026年利润增速或将转 正。在这一背景下，核心创始人以自有资金增持，向市场释放了对未来业绩回暖与长期增长的坚定信 心。 迈瑞医疗认为，展望国内市场，短期的行业扰动无法避免，公司已经及时地调整了应对策略。首 先，公司认为国内业务最艰难的时刻已经过去；第二，当前的市场环境给了迈瑞加速国产扩容和加快行 业集中度提升这一历史性机遇，因此公司将国内业务考核的重心放在了市场份额上，尤其是重点考核 IVD业务大规模突破大样本量客户，国内各项业务的市占率均在稳步提升；第三，公司持续倾斜资源投 入在流水型业务和国际市场。微创外科中的高值耗材超声刀、腔镜吻合器有望从今年开始在国内放量， 这部分业务的市场容量远比传统生命信息与支持业务要大，同时未来的成长性也要比传统业务更强，并 且得益于海外高端客户的加速突破，国际业务后续的增长也将提速。 目前，迈瑞医疗正全力冲击全球医疗器械排名 ...

Core Insights - The report highlights the growing market for surgical staplers, particularly in minimally invasive surgery, driven by advancements in medical technology and increasing demand for precision and safety in surgical procedures [2][6][7] Market Overview - The global stapler market is projected to reach USD 9.82 billion by 2024, with a compound annual growth rate (CAGR) of 3.8% from 2019 to 2024 [5] - The electric laparoscopic stapler segment is expected to grow significantly, reaching USD 2.21 billion by 2024, with a CAGR of 13.0% during the same period [5] - By 2030, the global stapler market is anticipated to expand to USD 12.69 billion, with the electric laparoscopic stapler market projected to reach USD 4.66 billion, representing a CAGR of 13.2% from 2024 to 2030 [5] China Market Insights - The Chinese stapler market is expected to reach CNY 9.82 billion by 2024, with a CAGR of 8.1% from 2019 to 2024 [6] - The electric laparoscopic stapler market in China is projected to grow to CNY 4.82 billion by 2024, accounting for 49.1% of the total market, with a remarkable CAGR of 44.4% [6] - By 2030, the market size is forecasted to increase to CNY 16.67 billion, with the electric laparoscopic stapler segment expected to reach CNY 11.72 billion, representing a CAGR of 16.0% [6] Industry Trends - The report indicates a shift towards electric laparoscopic staplers, which are expected to gradually replace traditional open staplers due to their advantages in minimizing surgical trauma and enhancing recovery times [4][7] - The increasing penetration of minimally invasive surgeries in China, currently at 14.2%, is expected to rise significantly, aligning more closely with the over 50% penetration rate seen in the United States [7] - The Chinese government is actively supporting the domestic medical device industry through various policies, which is expected to enhance the market share of local manufacturers [6][9] Technological Advancements - Electric laparoscopic staplers are noted for their advanced features, including automated and standardized operations, which reduce variability and improve surgical outcomes [4][8] - The demand for smart and efficient surgical instruments is driving the development of electric laparoscopic staplers, which are seen as the future direction of the stapler market [8] Competitive Landscape - Domestic manufacturers are increasingly competing with imported brands, as local products reach comparable technological levels [6][9] - The establishment of a comprehensive supply chain for staplers in China is facilitating the export of domestic products to international markets, enhancing their global competitiveness [9]

Core Viewpoint - Dongxing Medical (301290) announced on September 26 that it plans to acquire 90% of Wuhan Yijiaobao Biological Materials Co., Ltd. through cash payment, which, if successful, will make Wuhan Yijiaobao a subsidiary of Dongxing Medical. This transaction is expected to constitute a major asset restructuring [1][6]. Group 1: Acquisition Details - The acquisition involves signing a "Share Purchase Intent Agreement" with all shareholders of Wuhan Yijiaobao, a high-tech enterprise focused on the R&D, production, and sales of high-end orthopedic and biomedical materials [5][6]. - The transaction is still in the preliminary planning stage, requiring further verification and negotiation of the transaction terms. Both the listed company and the target company must complete necessary internal and external decision-making and approval processes [6]. Group 2: Company Background - Dongxing Medical is a leading enterprise in the field of laparoscopic staplers, with a market capitalization of 2.801 billion yuan as of September 26, closing at 27.96 yuan per share [4]. - The company primarily engages in the R&D, production, and sales of surgical medical devices, including laparoscopic staplers and surgical equipment [7]. Group 3: Financial Performance - In the first half of 2025, Dongxing Medical reported revenue of approximately 183 million yuan, a year-on-year decrease of 14.17%, and a net profit attributable to shareholders of approximately 30.29 million yuan, down 36.47% year-on-year [7]. - The company announced the termination of its initial public offering fundraising project related to "Zihang Medical Device Components Intelligent Manufacturing and Expansion Project" and postponed the project "Weike Medical Minimally Invasive Surgical New Product Project" to December 31, 2027 [7].

Core Viewpoint - The company has successfully increased its market share in the in vitro diagnostics (IVD) sector while maintaining stable gross margins, thanks to its core technology and strategic responses to national procurement policies [1] Market Share and Procurement - Since the second half of 2021, the company has actively participated in multiple centralized procurement projects, leveraging its multi-product line advantage in the IVD field to expand market share [1] - The company's market ranking in the chemiluminescence business has improved to third place domestically, while its biochemical business has surpassed a 15% market share for the first time [1] - The company has successfully won multiple bids for high-value consumables in 2024, including ultrasound knives and laparoscopic anastomosis devices, breaking into top-tier hospitals [1] Profitability and Cost Management - The company has managed to maintain its gross margin despite increased market share, primarily due to its mastery of core technologies [1] - The company aims to reduce the cost of chemiluminescence reagents by at least 50% over three years through increased self-manufacturing of core raw materials [1] - The introduction of new high-end ultrasound devices has allowed the company to double the price compared to previous models due to significant improvements in image performance [1] Innovation and Marketing - The company's technological innovations are increasingly competitive with imported brands, with some products leading in technology, which accelerates the acquisition of high-end clients [1] - The strategy to increase the revenue share of flow-type businesses, such as IVD reagents and high-value consumables, is expected to positively impact future profitability [1] Employee Engagement and Management - The company conducts regular employee surveys to assess management effectiveness and drive improvements, with a participation rate of 92.64% in the latest survey [1] - Survey results indicate that 84.78% of employees are engaged, and 80.23% express overall recognition of the company's management, culture, and development [1] - Approximately 89.16% of employees are confident in the company's future development [1]

Core Viewpoint - Mindray Medical's H1 2025 net profit attributable to shareholders is 5.069 billion yuan, a decrease of 32.96%, with Q2 net profit at 2.440 billion yuan, down 44.55% [1] Group 1: Market Performance - The international market shows steady growth, while the domestic market is under short-term pressure, awaiting a turning point [1] - Tender activities have seen a recovery in the first half of the year, with expectations for significant improvement in the domestic market in Q3 [1] Group 2: Product Development - In H1 2025, the company plans to launch 8 new chemiluminescence reagent products, increasing the total number of NMPA-approved products to 88 [1] - The MT8000 production line has received 185 new orders and nearly 100 new installations, with an annual installation target of 200 sets [1] Group 3: Business Growth - This year marks a significant growth year for minimally invasive surgical core products such as ultrasonic knives and endoscopic staplers, providing strong momentum for long-term growth in this business segment [1] Group 4: Valuation - Based on the DCF model, the overall valuation of the company is estimated at 353.9 billion yuan, with a target price of approximately 292 yuan, corresponding to a PE ratio of 27X for 2026 [1]